Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act
Summary
H.R. 5355 is an early-stage authorization bill with no appropriations attached, requiring HHS rulemaking to promote newborn liver disease screening. Revenue impact for diagnostic companies is structurally contingent on future funding and state adoption. Current market data shows diagnostic stocks in a short-term downtrend, with the bill too nascent to influence price action.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.H.R. 5355 is an early-stage authorization-only bill with no appropriations—zero dollars committed to any company.
- 2.The legislative path from introduction to revenue generation for diagnostic companies requires years and multiple independent actions (committee passage, floor votes, Senate, President, HHS rulemaking, state adoption).
- 3.Recent price action in $TMO, $DGX, $LH, and $ILMN shows no correlation to this bill; it is too early-stage and unfunded to move markets.
Market Implications
The current market data shows diagnostic stocks in a short-term downtrend with no discernible impact from H.R. 5355. closed at $474.19, down 3.53% over 30 days, with a sharp drop from $526.60 on April 17 to the current level—a decline driven by broader market factors, not healthcare policy. at $194.79 and at $261.31 are similarly flat-to-negative over the same period. at $125.90 is the only ticker showing a 30-day gain (+2.14%) but remains well below its 52-week high of $155.53. For retail investors, the market is pricing these companies on earnings expectations, clinical trial outcomes, and macroeconomic conditions—not on an unfunded early-stage bill referred to committee. There is no actionable trade signal from this legislation at present. Investors should monitor for committee hearings or a Senate companion bill as indicators of genuine legislative momentum, which would warrant a reassessment.
Full Analysis
H.R. 5355, the Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act, was introduced in the House on September 15, 2025, by Rep. Costa (D-CA) and referred to the House Committee on Energy and Commerce. The bill directs the HHS Secretary to carry out activities promoting newborn liver disease screenings, specifically citing routine direct-bilirubin measurement in heel-stick blood spot panels. As of the latest action on September 18, 2025, the sponsor delivered introductory remarks. The bill remains in the earliest legislative phase—no hearings, no markups, no Senate companion, and no appropriated funding.
The money trail is the critical fact here: this bill authorizes policy direction but contains no funding authorization numbers. Authorization without appropriation is a legislative statement, not a budget allocation. Any actual spending would require a separate appropriations bill, a Centers for Medicare & Medicaid Services (CMS) reimbursement determination, or state-level public health funding. The path from this bill to revenue for diagnostic companies requires at minimum: (1) committee markups and floor passage in the House, (2) Senate introduction and passage, (3) Presidential signature, (4) HHS rulemaking (typically 18-36 months), and (5) state adoption into standard newborn screening panels. That timeline, if it proceeds at all, extends years into the future.
Structural beneficiaries if the bill were to eventually pass with funding include Thermo Fisher Scientific as a supplier of clinical chemistry analyzers and reagents, Quest Diagnostics and Labcorp as reference laboratory operators, and Illumina as a provider of confirmatory sequencing. However, the mechanism of action is tenuous: newborn screening in the U.S. is administered by state public health laboratories, not commercial labs. The bill text explicitly centers on 'direct-bilirubin measurement in the newborn heel-stick panel'—a low-cost, widely available chemistry test already performed in most hospital labs. The addressable volume increase for a commercial lab is minimal without a structural shift in state testing models.
Real market data from April 2026 shows diagnostic stocks in a broad pullback: at $474.19 (-3.53% over 30 days), at $194.79 (-0.61% over 30 days), at $261.31 (-2.07% over 30 days), and at $125.90 (+2.14% over 30 days). The 30-day declines for , , and reflect broader market conditions, not legislative action on H.R. 5355. The 7-day changes are slightly negative for all but (+0.95%). There is no detectable price correlation with this bill.
Remaining legislative steps: the bill has not yet been scheduled for a committee hearing. As a House-only bill with 10 cosponsors and a junior Democratic sponsor (Rep. Costa, not a committee chair), momentum is low. The 119th Congress spans 2025–2027, but to become law, this bill must navigate the House Energy and Commerce Committee, full House vote, Senate Health, Education, Labor and Pensions Committee, full Senate vote, and conference committee reconciliation—all before the 119th Congress adjourns.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $1.5B Department of Homeland Security Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $2.9B Department of Homeland Security Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $2.9B Department of Homeland Security Grant
HUMAN SERVICES, NEW JERSEY DEPARTMENT OF: $16.9B Department of Health and Human Services Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $2.9B Department of Homeland Security Grant
GOVERNOR'S AUTHORIZED REPRESENTATIVE: $1.8B Department of Homeland Security Grant
DEPARTMENT OF SOCIAL SERVICES MISSO: $15.1B Department of Health and Human Services Grant
MINNESOTA DEPARTMENT OF HUMAN SERVICES: $14.1B Department of Health and Human Services Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →